Will Boston Scientific Corporation (NYSE:BSX) Be Able To Make Its Mark In China?

Posted by Chris Bell October 7, 2013 0 Comment 1153 views

The medical device market in China is expected to touch $38B by the year 2015. This is a 271% rise in comparison to 2009. The expectation also is that the imports to China in this field will increase and in 2012 itself there was a 15% rise. Boston Scientific Corporation (NYSE:BSX) is one of the world’s largest medical devices manufacturers and has a market cap of $15.70B. On 17 September, it set up a new research-center that will be used to develop and innovate products that will suit the Chinese market in a better way.

Late entrant

China is definitely one of the most lucrative emerging markets and Boston Scientific Corporation (NYSE:BSX) has walked into this space a little late. Companies like Johnson & Johnson and Medtronic have much larger operations and they have significant investments in the market. In 2011, J&J set up an innovation center where medical devices are being designed and developed. In addition, diagnostic products are also being developed here. All these products are targeted at emerging markets. Seems like Boston Scientific Corporation (NYSE:BSX) will have to pick up its game if it wants to stay ahead of the race in China.

Friday’s trading session

In Friday’s trading, Boston Scientific Corporation (NYSE:BSX) rose by 0.26%. The opening price of the shares was $11.66, which climbed to an intraday high of $11.75 and dipped to a close of $11.69. Approximately 8.98 million shares were traded on Friday while an average volume of 15.15 million shares were traded over a 30 day period.

About the company

Boston Scientific Corporation (NYSE:BSX) is engaged in developing and manufacturing as well as marketing of medical-devices that are used in a variety of interventional medical-specialties. In the year ended 31 December 2011, the company’s had 7 different business segments: 1) Interventional Cardiology, 2) CRM, 3) Endoscopy, 4) Peripheral Interventions, 5) Urology/Women’s Health, 6) Neuromodulation and 7) Electrophysiology.

About Chris Bell

Chris Bell is an investing reporter for GDP Insider. Chris covers financial markets and Wall Street, concentrating on developments affecting individual investors and their portfolios. Chris is also over consumer reporter and covers a wide variety of issues ranging from housing to immigration to urban poverty. Chris graduated from the University of Scranton with a degree in Communication and Philosophy. Chris's diligent investigations earned him the honor of being named "Best Reporter" once by the Headliners Foundation of Texas and once by the Houston Press Club.

View all post by Chris Bell Visit author's website

Write Your Comment